J. Anthony Ware - 15 Jun 2026 Form 4 Insider Report for First Tracks Biotherapeutics, Inc. (TRAX)

Reporting relationship: Director
Issuer ticker: TRAX
Reported as of: 15 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jun 2026, 16:05:23 UTC
Prior SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Ajim Tamboli, Attorney-in-Fact

Key filing fact

J. Anthony Ware filed Form 4 for First Tracks Biotherapeutics, Inc. (TRAX) on 17 Jun 2026.

Key facts

This page summarizes J. Anthony Ware's Form 4 filing for First Tracks Biotherapeutics, Inc. (TRAX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Jun 2026, 16:05.

Change

Previous filing in this sequence was filed on 12 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001715429 Primary reporting owner

Ware J. Anthony

Relationship: Director
Address: 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO
Signature: /s/ Ajim Tamboli, Attorney-in-Fact
Signature date: 17 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TRAX transaction

Common Stock

Options Exercise

Transaction value
Shares: +6,030
Change %: +63%
Price: $0.000000^*
Shares after: 15,660
Date: 15 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRAX transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
Shares: -6,030
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,030
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

Footnote F2

The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.